Margaret Cook, MD
Nephrology · Austin, TXNPI 1932174299
Payments from drug & device makers
Across 1,539 payments — averaging $736.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$523K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$179K
- CSL Behring$160K
- GSK$90K
- AstraZeneca$89K
- BD$59K
- plus $35K from 19 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 1,219 | $522,583 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $178,693 |
| CSL Behring | 52 | $159,750 |
| GSK | 16 | $89,926 |
| AstraZeneca(2 entities) | 40 | $89,084 |
| BD | 2 | $58,935 |
| Bayer | 69 | $30,539 |
| Biogen | 1 | $1,000 |
| Vifor Pharma, Inc. | 29 | $566 |
| Fresenius USA Marketing, Inc. | 20 | $438 |
| Amgen(2 entities) | 17 | $371 |
| Novartis | 12 | $339 |
| Aurinia Pharma U.S., Inc. | 11 | $279 |
| Otsuka America Pharmaceutical, Inc. | 13 | $267 |
| ANI Pharmaceuticals, Inc. | 8 | $169 |
| Mallinckrodt Hospital Products Inc. | 6 | $167 |
| Travere Therapeutics, Inc. | 5 | $133 |
| OPKO Pharmaceuticals, LLC | 5 | $82 |
| Ardelyx, Inc. | 3 | $75 |
| Boehringer Ingelheim | 2 | $53 |
| Veloxis Pharmaceuticals, Inc. | 2 | $52 |
| Daiichi Sankyo Inc. | 1 | $28 |
| Genentech USA, Inc. | 1 | $20 |
| Nxstage Medical, Inc. | 1 | $19 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$1,133,584 in reported general payments places this provider in the 95th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Austin
- Judith BettsAustin$3.7M
- Pablo PergolaSan Antonio$14.2M
- German HernandezEl Paso$9.7M
- Sreedhar MandayamHouston$7M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Marializa BernardoHouston$4.2M
- Wesley CalhounSan Antonio$3.5M
- Adam FromeThe Woodlands$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.